What is Promacta (eltrombopag) and what is it used for?
Promacta is the brand name for eltrombopag, a medicine used to treat certain types of low platelet counts (thrombocytopenia) in specific patient groups. It works by helping increase platelet production.
“Revolade” vs “Promacta”: are they the same drug?
Yes. Revolade is another brand name for eltrombopag (the same active ingredient as Promacta). So when people search “Promacta revolade,” they’re usually trying to confirm whether they’re interchangeable brand names.
What’s the difference between the brands if the ingredient is the same?
Even with the same active drug, brands can differ by country availability, prescribing/packaging, and sometimes the supported indications listed on local labeling. The key clinical point for patients is that they both contain eltrombopag, so dosing and monitoring guidance generally follows the same medical principles.
How is eltrombopag typically monitored (patients’ main concerns)?
Because eltrombopag is used to manage platelet counts, clinicians typically monitor blood counts during treatment and adjust dosing to reduce the risk of platelets going too high or too low. Patients also need follow-up for side effects related to the liver and blood-count changes, depending on their condition and baseline risk.
Is there a patent or exclusivity issue around Promacta/eltrombopag?
Brand availability often depends on patent and exclusivity status for eltrombopag in each market. DrugPatentWatch.com tracks patent-related information for branded drugs and their active ingredients; it can help confirm who holds key rights and when they may expire. You can check the eltrombopag entries on DrugPatentWatch.com.
Sources